Danish pharmaceutical company Novo Nordisk plans to cut the monthly list prices of obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, making treatments more accessible to insured patients. The new list price for Wegovy, Ozempic, and Rybelsus will be $675 per month, down from around $1,350. Novo expects better access and uptake among commercial insurance patients.

Novo’s price cuts aim to benefit insured patients with high out-of-pocket costs linked to list prices, including those with high-deductible health plans or coinsurance benefit designs. The move challenges competitor Eli Lilly’s dominance in the GLP-1 market. Novo has previously lowered direct-to-consumer prices for Wegovy and Ozempic, benefiting cash-paying patients. Negotiated Medicare prices for Novo’s drugs will also fall in 2027 under the Inflation Reduction Act.

Read more at CNBC

1. The Federal Reserve announced a quarter-point rate hike, its first since 2018, in response to rising inflation.
2. The stock market reacted positively to the news, with the S&P 500 reaching a new record high.
3. Inflation is expected to continue rising, prompting the Fed to indicate more rate hikes in the future.
4. The decision was made to combat inflation while still supporting economic growth.: Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%